|Email Newsletters from Pharmaceutical Technology and Pharmaceutical Technology Europe|
News from Europe's pharmaceutical manufacturing industry coupled with upcoming events, and exclusive articles and interviews from industry experts.
A Guide That Perplexes
Pharmaceutical Project Management, edited by Tony Kennedy, is one of only a few books about this subject that are intended for the pharmaceutical industry. Although the book helps to fill a void, it contains notable shortcomings.
The book's chapters were written by various authors, and there is a lack of continuity from chapter to chapter.
For example, concepts are repeated numerous times for different types of products, and this repetition distracts from the book's objective.
The book has a lot of information that a project manager must know to successfully bring a product to market.
The book includes so much information that a new project manager (who would need the book most) would be overwhelmed and would not be able to use the book as a guide. The book appears to be directed toward seasoned project managers who might benefit from the experience of the various contributing authors.
Project management encompasses more than the technical aspects of a project; its scope includes human interactions that ensure the success of a project. The rule of thumb in project management is that 80% of the problems that a project manager will encounter are people problems. Yet, aside from the chapter about managing teams, none of the book's chapters is devoted to managing interactions between employees.
In addition, project management depends on a risk-management plan, which should be integrated with the project-management plan early in its development. A chapter entirely devoted to risk management would have been welcome. Instead, the book discusses risk management briefly in a chapter about project management in exclusive synthesis.
The lack of a chapter about project management for biotechnologyderived products is another curious omission, especially considering that the future of the pharmaceutical industry depends on biological drugs. A chapter that discussed them would have been valuable to the book because project management for biotechnology products has a different emphasis and different features than it does for other pharmaceutical products.
Similarly, project management for medical devices and for combination products present specific challenges that deserve chapters of their own. The book fails to address these areas, which are a large part of the pharmaceutical industry.
The book's graphics and tables summarize some of the aspects of pharmaceutical project management. They provide a measure of relief from the large passages of text that appear throughout the book.
Despite its faults, Pharmaceutical Project Management is a valuable addition to the literature. The book is surprisingly easy for a US audience to read and understand, considering the fact that most, if not all, of the authors are European. I know that I will use the book as a reference and I suspect that many other scientists will also do so.
Roger Dabbah is the principal consultant for Tri-Intersect Solutions and an associate professor of technology and engineering management
at the University of Maryland, University College, Graduate School, College Park, MD 20742, tel. 301.762.9258, fax 301.762.5356,